Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neurol. 2007 Jul;254(7):849-53. Epub 2007 Mar 14.

Interferon beta in secondary progressive multiple sclerosis : daily clinical practice.

Author information

  • 12a planta EUI, Unitat de Neuroimmunología Clínica Hospital Universitario Vall d'Hebron, Psg Vall d'Hebron 119-120, 08035 Barcelona, Spain. jrio@vhebron.net

Abstract

BACKGROUND AND OBJECTIVE:

Observational studies may provide additional information about the behaviour of different drugs in the post-marketing period. We present the data from a cohort of secondary progressive multiple sclerosis (SPMS) patients treated with interferon beta (IFNbeta-1b) at our MS clinic.

METHODS:

This was an independent, open-label, non-randomised, observational study. Within the period 1998 to 2005, all patients with SPMS who started therapy with IFNbeta-1b at our centre were studied. Each patient was included in a follow-up protocol collecting demographic and baseline clinical data.

RESULTS:

We studied 146 SPMS patients with a median follow-up of 60 months. Over the total study period, 62.2% of patients had confirmed progression. The analysis of the time to con- firmed progression showed that patients with two or more relapses in the 2 years before IFNbeta initiation, had a higher risk of disability increase than those patients with less than two relapses (p = 0.002). Multiple regression analysis showed disease activity in terms of relapses as the only factor to predict increase of disability during the follow-up period. A significant proportion of patients (36%) stopped treatment during the follow-up period. IFNbeta was safe, although some unexpected adverse events were observed.

CONCLUSIONS:

A higher disease activity before the beginning of treatment with IFNbeta in SPMS patients with a given EDSS rank could identify those with faster disability progression after treatment initiation.

PMID:
17361342
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk